January 19, 2010 (FinancialWire) — Swiss biopharmaceutical firm Anavex Life Sciences Corp. (OTCBB: AVXL) has appointed Cameron Durrant as Executive chairman of its board of directors. Most recently, Durrant spent almost three years as Worldwide vice president, Infectious Diseases, Global Strategic Marketing at Johnson & Johnson (NYSE: JNJ).

He has also been CEO of two specialty pharmaceutical companies, PediaMed and Spherics.

In his new capacity, Durrant will work with Anavexmanagement and the board on executing the pre-clinical and clinical development plans for the company’s pipeline, corporate and business development, investor/public relations and prepare Anavax to relocate its corporate headquarters to the USA.

Anavex Life Sciences is a publicly traded biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of cancer and neurological diseases such as Alzheimer’s, epilepsy and depression.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.